# The potential application of the cannabinoid Beta-caryophyllene in glioblastoma therapy > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/beta-caryophyllene-glioblastoma-therapy-potential/ > **Published:** 2021-03-23T14:24:51-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:17:11-04:00 > **Clinical Summary:** Explore beta-caryophyllene glioblastoma therapy as a promising approach targeting CB2 receptors to inhibit tumor growth and inflammation. --- ### Beta-Caryophyllene Inhibits Cell Proliferation through a Direct Modulation of CB2 Receptors in Glioblastoma Cells ​In Summary Glioblastoma (GBM) is an aggressive type of cancer of the brain and spinal cord, arising from cells called astrocytes, which normally support and nourish neurons. Currently, GBM treatment includes primary therapy, which is surgical removal of the tumor, followed by adjuvant therapy, which are radiotherapy and administration of the chemotherapy drug temozolomide. Despite this intensive treatment regimen, the median survival of patients remains at 5 years following initial diagnosis. Thus, new therapeutic strategies to improve disease prognosis as well as patients’ [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) are greatly needed. Recently, scientists have found evidence that Beta-caryophyllene (BCP), a constituent of the plant cannabis can serve as a potent tumor suppressor in glioblastoma, controlling both the rampant tumorous cell proliferation and inflammatory reactions characteristic of this disease. In particular, using two cell lines, one derived from a human glioblastoma and one derived from human glioma stem-like cells, researchers showed that treatment with BCP reduced the viability, inhibited the proliferation, and promoted the death of cancerous cells. Additionally, they also demonstrated that BCP treatment reduced the production of cytokines, pro-inflammatory agents through interfering with a signaling cascade involving various receptors and protein complexes in the brain. When the cannabinoid receptor type 2 (CB2) was blocked in experiments, those effects were lost, proving that BCP’s mechanism of actions in glioblastoma largely relies on its activation of this known target. In my opinion, through this study, not only do the scientists shed light on a potential application of the cannabinoid Beta-caryophyllene in glioblastoma treatment, but they also open up the possibility of application of similar cannabinoids in therapy for different cancers. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [An unknown cannabinoid receptor helps alleviate secondary brain damages through regulating microglial cells and astrocytes of the brain.](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) Discover how a novel cannabinoid receptor modulates brain cell activity to reduce secondary brain damage, offering insights into neuroprotection. [Read More](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) [Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psori](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/) Explore [cannabinoid effects](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) beyond CB1/CB2 receptors in inhibiting cell proliferation, highlighting therapeutic potential in skin conditions. [Learn More](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/) [Cannabidiol: Attenuation of behavioral and cognitive schizophrenia symptoms leads to potential clinical applications](https://cedclinic.com/cannabidiol-antipsychotic-effects-schizophrenia-research/) Review cannabidiol’s role in reducing schizophrenia symptoms, emphasizing its emerging clinical applications in [neuropsychiatric disorders](https://cedclinic.com/thc-exposure-neuropsychiatric-disorders-impact-study/). [Explore Article](https://cedclinic.com/cannabidiol-antipsychotic-effects-schizophrenia-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=The%20potential%20application%20of%20the%20cannabinoid%20Beta-caryophyllene%20in%20glioblastoma%20therapy&url=https%3A%2F%2Fcedclinic.com%2Fbeta-caryophyllene-glioblastoma-therapy-potential%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fbeta-caryophyllene-glioblastoma-therapy-potential%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=The%20potential%20application%20of%20the%20cannabinoid%20Beta-caryophyllene%20in%20glioblastoma%20therapy%20https%3A%2F%2Fcedclinic.com%2Fbeta-caryophyllene-glioblastoma-therapy-potential%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).